The oestrogen paradox: A hypothesis Hipoteza paradoksu estrogenowego

Endokrynologia Polska

Volumn 58, Issue 3, 2007, Pages 222-227

  Santen, Richard J ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Breast cancer risk; Menopausal hormonal therapy; Oestrogens

Indexed keywords

ESTROGEN;

BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HUMAN; POSTMENOPAUSE; REVIEW; RISK FACTOR; TIME; TREATMENT OUTCOME;

BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; POSTMENOPAUSE; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 38449093403     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Larsen R et al. Williams Textbook of Endocrinology. Santen RJ, editor. Endocrine Responsive Cancer. 19, 1797-1833. 2002. Philadelphia, Pennsylvania, W B Saunders Company.
2. Chen WY, Manson JE, Hankinson SE et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 2006; 166: 1027-1032.
3. Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial [see comment]. JAMA 2004; 291: 1701-1712.
4. Stefanick ML, Anderson GL, Margolis KL et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006; 295: 1647-1657.
5. Schairer C, Lubin J, Troisi R et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk [see comment] [erratum appears in JAMA 2000 Nov 22-29; 284: 2597]. JAMA 2000; 283: 485-491.
6. Beral V, Million Women SC. Breast cancer and hormone-replacement therapy in the Million Women Study [see comment] [erratum appears in Lancet. 2003 Oct 4; 362 (9390): 1160]. Lancet 2003; 362: 419-427.
7. Ingle JN, Ahmann DL, Green SJ et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 1981; 304: 16-21.
8. Peethambaram PP, Ingle JN, Suman VJ et al. Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Res Treat 1999; 54: 117-122.
9. Carter AC, Sedransk N, Kelley RM et al. Diethylstilbestrol: recommended dosages for different categories of breast cancer patients. Report of the Cooperative Breast Cancer Group. JAMA 1977; 237: 2079-2080.
10. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estrogen-only therapy [see comment]. Obstet Gynec 2006; 108: 1354-1360.
11. Magnusson C, Baron JA, Correia N et al. Breast-cancer risk following long-term oestrogen-and oestrogen-progestin-replacement therapy. Inter J Can 1999; 81: 339-344.
12. Santen RJ, Manni A, Harvey H et al. Endocrine treatment of breast cancer in women. [Review] [282 refs]. Endocr Rev 1990; 11: 221-265.
13. Song RX, Zhang Z, Mor G et al. Down-regulation of Bcl-2 enhances estrogen apoptotic action in long-term estradiol-depleted ER(+) breast cancer cells. Apoptosis 2005; 10: 667-678.
14. Song RX, Santen RJ. Apoptotic action of estrogen. Apoptosis 2003; 8 (1): 55-60.
15. Song RX, Mor G, Naftolin F et al. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17 beta-estradiol [see comment]. J Natl Cancer Inst 2001; 93: 1714-1723.
16. Jordan VC, Lewis JS, Osipo C et al. The apoptotic action of estrogen following exhaustive antihormonal therapy: a new clinical treatment strategy. [Review] [43 refs]. Breast 2005; 14: 624-630.
17. Jordan VC, Liu H, Dardes R. Re: Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17 beta-estradiol and the two faces of Janus: sex steroids as mediators of both cell proliferation and cell death [comment]. J Natl Cancer Inst 2002; 94: 1173-1175.
18. Lewis JS, Meeke K, Osipo C et al. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J. Natl Cancer Inst 2005; 97: 1746-1759.
19. Lewis JS, Osipo C, Meeke K et al. Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal. J Steroid Biochem Mol Biol 2005; 94: 131-141.
20. Liu H, Lee ES, Gajdos C et al. Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. J Natl Cancer Inst 2003; 95: 1586-1597.
21. Yao K, Lee ES, Bentrem DJ et al. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Can Research 2000; 6: 2028-2036.
22. Welch HG, Black WC. Using autopsy series to estimate the disease reservoir" for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med 1997; 127: 1023-1028.
23. Ryan JA, Coady CJ. Intraductal epithelial proliferation in the human breast-A comparative study. Can J Surg 1962; 5: 12-19.
24. Cavalieri E, Chakravarti D, Guttenplan J et al. Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Bioch Biophys Acta 2006; 1766: 63-78.
25. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006; 354: 270-282.
26. Fernandez SV, Russo IH, Russo J. Estradiol and its metabolites 4-hydroxyestradiol and 2-hydroxyestradiol induce mutations in human breast epithelial cells. Int J Cancer 2006; 118: 1862-1868.
27. Russo J, Russo IH. The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol 2006; 102: 89-96.
28. Russo J, Fernandez SV, Russo PA et al. 17-Beta-estradiol induces transformation and tumorigenesis in human breast epithelial cells. FASEB J 2006; 20: 1622-1634.
29. Zhao Z, Kosinska W, Khmelnitsky M et al. Mutagenic activity of 4-hydroxyestradiol, but not 2-hydroxyestradiol, in BB rat2 embryonic cells, and the mutational spectrum of 4-hydroxyestradiol. Chem Res Toxicol 2006; 19: 475-479.
30. Devanesan P. Catechol estrogen metabolites and conjugates in mammary tumors and hyperplastic tissue form estrogen receptor alpha knock-out (ERKO)/Wnt1 mice: implications for initiation of mammary tumors. Santen RJ BW, Korach K, Rogan EG CE, editors. Carcinogenesis 2001; 22: 1573-1576.